Scynexis-Color.png
SCYNEXIS to Present at the BIO Digital International Convention 2020
June 08, 2020 09:51 ET | Scynexis
Company presentation will highlight progress towards transitioning to a fully integrated commercial stage company with an initial focus on vaginal yeast infection JERSEY CITY, N.J., June 08, 2020 ...
Scynexis-Color.png
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales
June 02, 2020 08:00 ET | Scynexis
Appointment of seasoned women’s health marketing executive is a key step in the transition to a fully-integrated drug development and commercial company with initial focus on vaginal yeast infection ...
Scynexis-Color.png
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
May 11, 2020 08:50 ET | Scynexis
In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as...
Scynexis-Color.png
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
May 06, 2020 08:00 ET | Scynexis
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infectionsFindings indicate...
Scynexis-Color.png
SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
April 28, 2020 08:00 ET | Scynexis
JERSEY CITY, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Scynexis-Color.png
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
April 21, 2020 07:00 ET | Scynexis
Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpointsIbrexafungerp was generally safe and well-toleratedPositive results...
Scynexis-Color.png
SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement
April 13, 2020 08:54 ET | Scynexis
SCYNEXIS has the ability, at its discretion, to efficiently access up to $20 million of capital $20 million purchase agreement, combined with $10 million cash injection from recent sale of...
Scynexis-Color.png
SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital
April 09, 2020 08:53 ET | Scynexis
JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Scynexis-Color.png
SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020
March 26, 2020 08:00 ET | Scynexis
JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Scynexis-Color.png
SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
March 11, 2020 08:18 ET | Scynexis
Oral ibrexafungerp continues to advance in multiple indicationsNearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more...